Prestige Consumer Healthcare Inc. $PBH Position Cut by Boston Trust Walden Corp

Key Points

• Boston Trust Walden cut its Prestige Consumer Healthcare stake by 55.4% in the third quarter, selling 337,657 shares. It held 272,292 shares, worth about $12.49 million, at quarter-end.
• Prestige reported quarterly EPS of $1.13, beating the $1.07 consensus, while revenue of $336.31 million also topped estimates and rose 22.7% year over year.
• Analyst sentiment is mixed but consensus is Hold, with a $67.67 price target. The stock opened at $44.34, near its 12-month low of $42.62.

Boston Trust Walden Corp lessened its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 55.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 272,292 shares of the company's stock after selling 337,657 shares during the period. Boston Trust Walden Corp owned 0.57% of Prestige Consumer Healthcare worth $12,490,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of PBH. Barrow Hanley Mewhinney & Strauss LLC purchased a new position in shares of Prestige Consumer Healthcare during the 2nd quarter worth approximately $30,000. Versant Capital Management Inc lifted its stake in Prestige Consumer Healthcare by 47.9% in the 2nd quarter. Versant Capital Management Inc now owns 726 shares of the company's stock valued at $34,000 after buying an additional 235 shares in the last quarter. Cornerstone Planning Group LLC purchased a new stake in Prestige Consumer Healthcare in the 1st quarter valued at approximately $44,000. Pinnacle Wealth Planning Services Inc. lifted its stake in Prestige Consumer Healthcare by 69.3% in the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 1,153 shares of the company's stock valued at $53,000 after buying an additional 472 shares in the last quarter. Finally, Covestor Ltd grew its holdings in Prestige Consumer Healthcare by 45.6% during the 3rd quarter. Covestor Ltd now owns 1,589 shares of the company's stock valued at $73,000 after buying an additional 498 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Zacks Research downgraded Prestige Consumer Healthcare from a "strong-buy" rating to a "hold" rating in a research report on Thursday, October 29th. Weiss Ratings restated a "sell (d+)" rating on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 22nd. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $67.67.

Prestige Consumer Healthcare Price Performance

Prestige Consumer Healthcare stock opened at $44.34 on Friday. Prestige Consumer Healthcare Inc. has a 12-month low of $42.62 and a 12-month high of $71.07. The stock has a market capitalization of $2.10 billion, a P/E ratio of 12.05, a P/E/G ratio of 1.67 and a beta of 0.30. The firm's 50-day moving average is $48.34 and its two-hundred day moving average is $53.88. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 1.99.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported $1.13 earnings per share for the quarter, beating analysts' consensus estimates of $1.07 by $0.06. The business had revenue of $336.31 million during the quarter, compared to analyst estimates of $329.14 million. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The company's revenue was up 22.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.07 earnings per share. Equities analysts predict that Prestige Consumer Healthcare Inc. will post 4.56 earnings per share for the current year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc NYSE: PBH is a consumer healthcare company that develops, acquires, markets and distributes over-the-counter health and wellness products. Its portfolio is focused on established brands designed to address everyday healthcare needs, including digestive health, eye and ear care, oral care, pain relief, cold and allergy symptoms, feminine care and dermatological conditions.

The company's brands include Dramamine and Bonine for motion-sickness relief; BC and Goody's for pain relief; Clear Eyes and Murine for eye and ear care; Chloraseptic for sore-throat relief; Compound W for wart removal; Fleet for gastrointestinal health; and Summer's Eve for feminine care.

Want to see what other hedge funds are holding PBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.